|
WO2012107572A1
|
|
Method for the purification of a glycan and/or a glycoconjugate by chromatography using a stationary phase comprising cotton
|
|
CN102770765A
|
|
Reductive amination and analysis of carbohydrates using 2-picoline borane as reducing agent
|
|
WO2011038874A1
|
|
Method for releasing and labelling 0-glycans
|
|
GB201002082D0
|
|
Biological material
|
|
GB0907052D0
|
|
Immunotherapeutic molecules and methods
|
|
GB0904904D0
|
|
Angiogenesis methods, medicaments and agents
|
|
WO2009061182A1
|
|
Hla class ii pi4k2b mhags and application thereof
|
|
GB0820155D0
|
|
Genetic analysis
|
|
US7550138B1
|
|
Plasmodium mutant and vaccines including the mutant
|
|
WO2008018789A2
|
|
Methods and means for diagnosing and treatment of osteoarthritis
|
|
US2009220534A1
|
|
Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
|
|
CA2638822A1
|
|
Adir related polymorphisms and applications thereof
|
|
EP1896499A2
|
|
Hecgf-1 related polymorphisms and applications thereof
|
|
WO2006123929A2
|
|
Site-specific integration in cells of the mesenchymal lineage
|
|
WO2007091881A2
|
|
Methods and means for detection of mycobacterium leprae infections
|
|
EP2289516A1
|
|
Methods and means for the treatment of HPV induced intraepithelial neoplasias
|
|
WO2006132530A2
|
|
Methods and means for use in diagnostics and treatment of diabetes
|
|
EP1726962A1
|
|
Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
|
|
US2009028874A1
|
|
Synthetic Protein as Tumor-Specific Vaccine
|
|
WO03084999A1
|
|
Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
|
